TABLE: Inhalte


Titel Autor
Antiretroviral treatment outcomes and their predictors in a large cohort of HIV-Infected children in Sub-Saharan Africa
Maria Cristina Marazzi1, Andrea De Luca2, Massimo Magnano San Lio3, Ersilia Buonomo3, Paola Scarcella4, Paola Germano4, Gianni Guidotti4, Giovanna Paturzo4, An
Mortality of HIV-infected patients in the HAART era
Mario Sarcletti1, Margret Jöchl2, Stefanie Gogl3, Armin Rieger4, Maria Geit5, Bernhard Haas6, Robert Zangerle1
Risk of new AIDS defining events in patients with advanced immunodeficiency during suppressive HAART
Alexander Zoufaly1, Christina Kreuzberg1, Matthias an der Heiden2, Christian Kollan2, Osamah Hamouda2, Jan van Lunzen3
Erwartungen an den Arzt - optimale HIV/STD-Prävention aus der Sicht schwuler Männer
Angelika Wolf1, Julika Loss1, Steffen Taubert2
Trends in risk-taking and risk reduction among German MSM. Results of follow-up surveys “Gay Men and AIDS” 1991-2007
Axel J. Schmidt1, Michael Bochow1
HIV serosorting and the risk of sexually transmitted infections in men who have sex with men
Ulrich Marcus1, Axel J. Schmidt1
"EKAF" avant la lettre? ART-bezogene Risikomanagementstrategien bei MSM in Deutschland
Phil C. Langer1, Jochen Drewes2, Ursula von Rüden3, Angela Kühner1,4
Zu den Kontexten von HIV-Neuinfektionen bei schwulen Männern in Berlin zwischen 2003 und 2006. Interviews mit Neuinfizierten
Michael Bochow1
HIV-exponierte Schwangerschaften an zwei deutschen Schwerpunktzentren 2004 - 2008
Andrea Gingelmaier1, Ralph Kästner1, Milena Sovric1, Jan-Peter Siedentopf2, Cornelia Feiterna-Sperling3, Gundula Notheis4, Weizsäcker Katharina2
Association of effective control of HIV-1 with strong ctl selection pressure and a highly mutated nef in a HIV-1-infected patient
Katja Maurer1, Jan Schmökel2, Frank Kirchhoff2, Jennifer Etschel1, Sascha Antoni3, Kathrin Eismann1, Silke Bergmann1, Pia Rauch1, Karin Metzner4
Very rapid resonse kinetics to HLA-B57/58 gag-restricted CTL epitopes is asociated with slow diesease progression
Jan van Lunzen1,2, Julian Schulze zur Wiesch1,2, Philip Hartjen1,2, Ingrid Stahmer1,2
HLA-E restringierte Erkennung eines HIV-Peptids durch humane CD8(+) T-Zellen
Daniela Schulte1, Martin Vogel1, Bettina Langhans1, Christian Körner1, Benjamin Krämer1, Hans Dieter Nischalke1, Martin Coenen1, Tilman Sauerbruch1<
Frequency and phenotype of CD4+ FoxP3+ T regulatory cells is associated with disease progression in HIV-1 infected patients
Adriana Thomssen1, Philipp Hartjen1, Sandra Hertling1, Olaf Degen1, Stefan Schmiedel1, Dirk Meyer-Olsen2, Ansgar Lohse1, Joachim Hauber3, Jan van Lunze
Scheitert eine adäquate ökonomische Abbildung der stationären HIV-Fälle durch die G-DRGs an der niedrigen Prävalenz der HIV-Infektion in Deutschland?
Matthias Stoll1, Deutsche AIDS Gesellschaft
Direct costs for highly active antiretroviral treatment (HAART) regimens in the German ClinSurv multicenter cohort 1996 - 2008*
Matthias Stoll1, Christian Kollan2, Osamah Hamouda2, ClinSurv Study Group
Risk factors of "early“ and "late“ diagnosis of HIV infection in Austria
Mario Sarcletti1, Stefanie Gogl2, Margret Jöchl3, Armin Rieger4, Maria Geit5, Bernhard Haas6, Ninon Taylor7, Manfred Kanatschnig8, Robert Zangerle
Prevalence of potential drug-drug interactions in the Swiss HIV Cohort Study
Catia Marzolini1, Sara Gibbons2, Luigia Elzi1, Saye Khoo2, Bruno Ledergerber3, David Back2, Manuel Battegay1, Swiss HIV Cohort Study Members
Clinical outcomes of HIV-positive patients (PLWHA) having different income status: results of an analysis on basis of the KompNet cohort
Klaus Jansen1, Norbert H. Brockmeyer1,2, Verena Dlugay3, Matthias Stoll4, Ramona Volkert5, Jörg Gölz6, Thomas Buhk7, Andreas Carganico8, Peter
The influence of nucleoside free HAART on the treatment of chronic hepatitis C with pegylated interferon / ribavirin combination treatment
Martin Vogel1, Golo Ahlenstiel1, Gerd Klausen2, Thomas Lutz3, Dirk Schürmann4, Christoph Stephan5, Christoph Mayr6, Axel Baumgarten7, Peter Buggis
Successful antiretroviral therapy is associated with increasing HCV-specific T cell responses
Janine Rohrbach1, Gillian Harcourt2, Silvana Gaudieri3, Nicola Robinson2, Amalio Telenti4, Matthias Egger5, Huldrych Günthard6, Paul Klenerman2, Hansjakob
Retrospective analysis of orthotopic liver transplantation in human immunodeficiency virus (HIV)-Positive patients in German transplant centers
Evrim Anadol1, Christoph Berg2, Markus Bickel3, Bernd Salzberger4, Matthias Stoll5, Alexander Zoufaly6, German OLTX-HIV-Group
Outcome of AIDS-related lymphoma depends on CD20 expression
Christoph Wyen1, Gerd Fätkenheuer1, Björn-Erik Ole Jensen2, Michael Sabranski3, Timo Wolf4, Jan Siehl5, Birgit Ross6, Markus Müller7, J
HIV-associated Hodgkin's lymphoma (HIV-HL): Interim analysis of a prospective multicenter trial
Marcus Hentrich1, Anja Masuhr2, Christoph Wyen3, Jan Siehl4, Timo Wolf5, Jan-Christian Wasmuth6, Ansgar Rieke7, Dagmar Assmann8, Anke Meyer9
Low sensitivity of an interferon-gamma releasing assay (Elispot-TB) for the diagnosis of latent tuberculosis in HIV-infected individuals
Luigia Elzi1, Ingrid Steffen2, Hansjakob Furrer3, Stefano Bassetti4, Manuel Battegay1
Specific HIV-1 env traits and association with virologic control in vivo
Beda Joos1, Philip Rieder1, Marek Fischer1, Herbert Kuster1, Peter Rusert2, Alexandra Trkola2, Satish K Pillai3, Joseph K Wong3, Rainer Weber1
Genotypic activity of Etravirine in patients failing on Efavirenz or Nevirapine: the Swiss HIV cohort study (SHCS)
Alexandra U. Scherrer1, Barbara Hasse1, Viktor von Wyl1, Sabine Yerly2, Jürg Böni3, Philippe Bürgisser4, Thomas Klimkait5, Heiner C. Bucher6
Does the addition of rPRT to GRT help in choosing regimens with better virologic response?
Tracy Glass1, Jan Fehr2, Severine Louvel3,4, Jürg Böni5, Sabine Yerly6, Philippe Bürgisser7, Heiner Bucher1, Thomas Klimkait3
Targeting SEVI-mediated enhancement of virus infection to reduce sexual transmission of HIV-1
Ilona Hauber1, Heinrich Hohenberg1, Joachim Hauber1
Control of HIV by CCR5Δ32/Δ32 stem cell transplantation - an update
Kristina Allers1, Gero Hütter2, Jörg Hofmann3, Christoph Loddenkemper4, Thomas Schneider1
Preclinical evaluation of VIR-576, a novel antiretroviral drug candidate blocking the HIV-1 gp41 fusion peptide
Wolf-Georg Forssmann1, Knut Adermann2, Ludger Ständker1, Matthias Stoll1, Yu-Han The1, Frank Kirchhoff3, Jan Münch3, Reinhold Ernst Schmidt1
A neutralizing monoclonal antibody for HIV gene therapy
Khalid Al-Shoba1, Kimbel Janine1, Lisa Egerer1, Sebastian Newrzela1, Tobias Maetzig2, Axel Schambach2, Dorothee von Laer1
AIDS und Immigranten aus ehemaliger Sowjetunion (ESU): erste Erkenntnisse über Wissen und Inanspruchnahme von AIDS-Beratungsangeboten in Deutschland
Laura Kouznetsov1, Alexander Vasilevich Kuznetsov2, Thomas Ruzicka3, Stefan Zippel1
What do men who have sex with men in Germany know about the most common sexually transmitted infections?
Ulrich Marcus1, Axel J. Schmidt1
Internetgestützte Sexualkontakte und HIV-Infektionsrisiko
Michael Bochow1, Axel J. Schmidt2
Late and early presenters in the German KompNet Cohort - a comparison of sociodemographic variables
Ulrich Marcus1, Claudia Michalik2, Norbert Brockmeyer3,4, Verena Duglay5, Martin Zeitz6, Elke Lauenroth-Mai7, Martin Hower8, Stefan Reuter9, Jürgen
Support needs and access to services relating to sexual and reproductive health of people living with HIV/AIDS (PLWHA) in Switzerland
Sibylle Nideröst1, Daniel Gredig1, Christophe Roulin1, Martin Rickenbach2, the Swiss HIV Cohort Study and the Eurosupport Study Group
Gender differences in social support and mental health among HIV positive women and men living in Europe
Christiana Nöstlinger1, Victoria Gordillo2, Erin Fekete3, Tom Platteau1, Eurosupport V Study Group
Optimierung einer zielgerichteten, subsidiären Einzelhilfe durch die Deutsche AIDS Stiftung (DAS) durch eine Vernetzung mit Daten aus dem Kompetenznetz HIV/AIDS
Matthias Stoll1, Volker Mertens2, Claudia Michalik3, Klaus Jansen4, Norbert Brockmeyer5, Hans Jäger6, Andreas Plettenberg7, Arend Moll8, Stephan D
Perceived threat of HIV/Aids and knowledge of highly active antiretroviral therapy (HAART) in heterosexual men and MSM in Germany
Ursula von Rueden1
HIV-related travel restrictions
David Hans-U. Haerry1, Peter Wiessner1, Karl Lemmen2
Chancen und Grenzen des Internet für eine erweiterte HIV/AIDS-Prävention, HIV- und STD-Beratung sowie Partizipation der Zielgruppen
Claudia Corsten1
Keeping a grip on HIV: collaborative medication and symptom management experiences of persons living with HIV in Switzerland
Dunja Nicca1,2, Jan Sven Fehr3, Pietro Vernazza4, Rebecca Spirig5,6
Motivational patterns of HIV testing among MSM: Implications for prevention
Phil C. Langer1, Jochen Drewes2, Ursula von Rüden3
Gesundheitsbezogene Lebensqualität (QoL) HIV-positiver Patienten in einer Schwerpunktpraxis
Stefan Mauss1, Julia Henke1, Florian Berger1, Petra Hegener1, Guenther Schmutz1
Die gesellschaftliche Regierung der HIV-Infektion. Eine empirisch-genealogische Studie
Katrina Pfundt1
Niedrigschwellige Beratung von HIV-Patienten als interdisziplinäre Kooperation zwischen Ärzten von Schwerpunktpraxen und psychosozialen Beratern einer Selbsthilfeorganisation
Leo Locher1,2, Gaby Knecht1, Imke Klein2, Michael Bohl2
HIV-related vulnerability dynamics and syndemic productions in homosexual life contexts
Phil C. Langer1, Angela Kühner1,2
Die hausärztliche Betreuung HIV-Positiver aus Sicht der betroffenen Patienten
Heike Nestel1, Burkhard Schappert1, Michael Jansky1, Ulrich Seifert1
Der kleine Unterschied - Symptomerfahrung bei HIV-positiven Personen mit oder ohne Bezugsperson
Katharina Fierz1, Kimberly Moody2, Dunja Nicca3,4, Tracy Glass5, Manuel Battegay6, Rebecca Spirig1,4
Fortbildungsbedarf von Hausärzten im Bezug auf HIV/AIDS
Burkhard Schappert1, Michael Jansky1, Stefan Graafen1
Die Bedeutung von HIV in der hausärztlichen Praxis
Burkhard Schappert1, Michael Jansky1, Stefan Graafen1
Ermittlung von Patientenpräferenzen bei der Therapie von HIV/AIDS
Matthias Nübling1, Hans-Joachim Lincke1, Verena Donatz2, Axel Christian Mühlbacher1, Kompetenznetz HIV
Lebensqualität von HIV/Aids Patienten und Patientinnen
Daniela Fuchs1
HIV und Aids und Arbeit/Beschäftigung - Situation HIV-positiver Frauen in Deutschland
Gaby Wirz1, Ulrike Sonnenberg-Schwan2, Harriet Langanke3, Dagmar Klimesch4, Netzwerk Frauen und Aids Deutschland
Spiritual and mind-body beliefs as barriers and motivators to HIV-treatment decision-making and medication adherence?
Heidemarie Kremer1, Gail Ironson1, Martina Porr1
Beyond being not wanting to be a guinea pig: barriers and motivators to participation of minority women in clinical trials
Heidemarie Kremer1, Gail Ironson1, Martina Porr1,2
Coping-Prozesse bei HIV/AIDS-Patienten aus der Perspektive westlicher und buddhistischer Psychologie
Carsten Klöpfer1
Preparing for the long run - Ein Wochenendseminar über HIV Therapie und Prävention für internationale Ärzte der nächsten Generation
Tessa S Lennemann1, Rose Marie Beck2, Christoph Königs3, Holger Pfister4, Gabriele Nisius1, Mira Gruber1, Lena Kroeker5, Reinhard Brodt6
Die Regierung der HIV-Infektion. Eine empirisch-genealogische Studie
Katrina Pfundt1
A regional multi-sectoral HIV prevention and AIDS care programme approach to keep the Western Balkans low-prevalent
Bettina Schwethelm1, LeeNah Hsu1, Olimbi Hoxhaj2, Genc Ymerhalili3
Public acceptence of harm reduction as a major limitation for HIV prevention in Bashkortostan
Zulfia Galieva1, Dunja Nicca2, Johannes Schläpfer3, Matthias Schlegel2, Pietro Vernazza2, Bettina Mäschli4, Infekt Team Schweiz Russland (ITSR)
Krankheit als Schuld: Paradigmenwechsel in der Medizin?
Stefan Nagel1
Berührungsängste verlieren, Professionalität gewinnen - ein Trainingsprogramm des HIVCENTER für Lernende in Gesundheitsfachberufen
Kathleen Mantzsch1, Patricia Luczkowski2, Michaela Bracone1, Tessa Lennemann1, Claudia Kircher1, H.R. Brodt1
Ergebnisse einer kunsttherapeutischen Studie
Regine Merz1, Norbert Brockmeyer2, David Aldridge1, Kompetenznetz HIV/AIDS
Working toward a world without AIDS: how social marketing inspires long-term cultural change
Ruth E. Massingill1
Prävention für Menschen mit HIV: Sexualverhalten und beeinflussende Faktoren
Dunja Nicca1, Synove Daneel1, Pietro Vernazza1
BuT - Beratung und Test: Ein landesweites Projekt zur HIV-Primärprävention in der Vorort-Arbeit für MSM in Nordrhein-Westfalen
Michael Wurm1, Reinhard Klenke1, Dirk Meyer1
Mach´s mit 2009: Emotionen und Informationen - ein neues Kommunikationskonzept zur bevölkerungsweiten und zielgruppenspezifischen HIV/AIDS-Prävention
Claudia Corsten1, Wolfgang Müller1
Stufen der Partizipation in der HIV-Prävention
Michael T. Wright1, Martina Block1, Hella von Unger1, Karl Lemmen2
Condom use among heterosexual HIV positive men and women: what's in a steady relationship? Results of the Eurosupport V study
Christiana Nöstlinger1, Sibylle Nideröst2, Daniel Gredig2, Tom Platteau1, Matthias Müller3, Eurosupport V Study Group & Swiss HIV Cohort Study
Glance over the fence - and back! BORDERNETWork- further development of hands-on HIV/AIDS/STI prevention, diagnostic and treatment in Europe
Elfriede Steffan1, Tzvetina Arsova Netzelmann1
How do we know what works? Assessment survey on quality assurance in the frame of National HIV/AIDS Prevention Programmes
Tzvetina Arsova Netzelmann1, Elfriede Steffan1, Helene Reemann2
Development of an HIV prevention flyer for illiterate persons and individuals with functional illiteracy
Synove Daneel1, Adjara Tina2, Johannes Schlaepfer3, Patrick Schmid4, Pietro Vernazza4, Dunja Nicca4
Perspektiven der HIV-Prävention mit vulnerablen Jugendlichen: Erfahrungen aus einem Modellprojekt im Berliner Jugendarrest
Thomas Wilke1, Phil C. Langer1, Birte Seffert1, Stefan Müller1, Dorothee Krings1, Susann Bollmann1, Christina Auffenberg1, Nils Groß1, Patrick
Mission possible - doch nicht möglich? Effekte der Aktion 3 Monate Safer Sex ein Jahr danach
Roger Staub1, Steven Derendinger1, Martin Gebhardt1, Thomas Bucher2, Christophe Fraser3, Hugues Balthasar4
Recurring patterns in safer sex discussions in forums of sex workers' clients
Harriet Langanke1
Feasibility study for a European internet platform in the field of HIV prevention and sexual health
Christiane Firnges1, Elfriede Steffan1, Ursula von Rüden2
Safe Environment. (SE) Entwicklung von Standards zur HIV-Prävention in kommerziellen Sex-Betrieben für MSM. Leitfaden zur Standardisierung und bundesweiten Umsetzung
Franz-Josef Ehrle1, Herbert Engel1
“Hard to reach” oder how to reach - anonymer HIV-Test für Migrantinnen in unterschiedlichen Settings
Heidrun Nitschke1, Anna Knappik1, Jan Leidel2
Die Rolle der Postexpositions-Prophylaxe in der Prävention mit MSM: Ergebnisse einer Befragung von HIV-Schwerpunktärzten
Jochen Drewes1, Phil C. Langer2, und das Kompetenznetz HIV/Aids
Ergebnisse einer Befragung der Aidshilfen zu Partizipation und Kooperation in der HIV-Prävention mit Migrant/innen
Hella von Unger1, Silke Klumb2, Michael T Wright1
Anonyme HIV-Testberatung und Migrantinnen - wer findet den Weg?
Heidrun Nitschke1, Anna Knappik1, Jan Leidel2
Klientenorientierte Erhebung zum HIV-Test-Angebot (Hintergründe und Motivation); Orientierung zur Verbesserung des Angebots
Dagmar Charrier1
Die Deutsch-Ukrainische Zusammenarbeit im Bereich HIV/AIDS
Jenny Bluhm1
Microbicide formulations in development
Thomas Mertenskoetter1, Joseph Romano1, Paulina Kaptur1
Internet-Plattform zur Partizipativen Qualitätsentwicklung (PQE) in der HIV-Prävention
Hella von Unger1, Corinna Gekeler2, Martina Block1, Karl Lemmen2, Michael T Wright1
Nachwuchsförderung im HIVCENTER - Medizinstudenten als Zielgruppe für HIV Prävention und praktische medizinische Ausbildung
Claudia Kircher1, Sebastian Kessler1, Nathalie Schmitz2, Tobias Kisch2, Reinhard Brodt3, Tessa Lennemann1
„Handbuch Jugendprävention“: ein neues Instrument der Qualitätssicherung in der Präventionsarbeit
Thomas Wilke1, Phil C. Langer2, Birte Seffert3, Stefan Müller3, Sarah Arriagada2, Robin Möser2, Stefan Richter2, Franziska Gutsche2, Schoolwor
HIV-Infektion im Bewusstsein von Studierenden: Ergebnisse einer Pilotstudie
Alexander Vasilevich Kuznetsov1,2, Laura Kouznetsov1, Uwe Matterne3, Rafael Mikolajczyk2, Thomas Ruzicka4, Stefan Albin Zippel5, Alexander Krämer6
Molecular epidemiology reveals long-term changes in HIV-1 transmission in Switzerland
Roger Kouyos1, Viktor von Wyl1, Sabine Yerly2, Jürg Böni3, Patrick Taffé4, Cyril Shah3, Philippe Bürgisser5, Thomas Klimkait6, Raine
HIV-serosorting among German men who have sex with men. Implications for community prevalence of STIs and HIV-prevention
Axel J. Schmidt1, Ulrich Marcus2, Jürgen Töppich3, Michael Bochow1
First preliminary results and operational findings from the German HIV incidence study at Robert Koch-Institute
Ruth Zimmermann1, Jörg Bätzing-Feigenbaum1, Stephan Loschen2, Silvia Gohlke-Micknis1, Oscar Kamga Wambo1, Claudia Kücherer2, Osamah Hamouda1
Epidemiology of herpes simplex virus infections (HSV) in a cohort of recently HIV-1 infected patients from the German HIV-1 seroconverter study
Christina Lindemann1, Claudia Houareau1, Nadine Spielmann1, Barbara Bartmeyer1, Claudia Kücherer2, Osamah Hamouda1, German HIV-1 Seroconverter Group
Line-immunoassay-based differentiation of recent and older HIV-1 infection among all newly diagnosed patients in Switzerland
Jörg Schüpbach1, Christoph Niederhauser2, Sabine Yerly3, Stephan Regenass4, Lukas Matter5, Philippe Bürgisser6, Meri Gorgievski7, Ingrid Steffen
Stable percentages of CD4+ and CD8+ T-cell in Elite Controllers, but not intermediate Controllers of HIV-1 replication
Clara Lehmann1, Pia Flossdorf1, Dirk Meyer-Olson2, Reinhold E Schmidt2, Pavel Khaykin3, Stefan Mauss4, Jan van Lunzen5, Christoph Stefan3, Juergen Rock
Risk factors for HIV associated Hodgkin's lymphoma during HAART in a large observational study (ClinSurv)
Alexander Zoufaly1, Hans-Jürgen Stellbrink2, Matthias an der Heiden3, Christian Kollan3, Christoph Wyen4, Christian Hoffmann2, Jan van Lunzen5, Osamah Hamouda
The connection domain mutation N348I in HIV-1 reverse transcriptase may compensate for M184V-mediated deficits in viral fitness
Viktor von Wyl1, Maryam Ehteshami2, Philippe Bürgisser3, Monique Nijhuis4, Lisa Demeter5, Sabine Yerly6, Jürg Böni7, Thomas Klimkait8, Ma
Prognostic factors of survival in HIV-infected individuals with progressive multifocal leukoencephalopathy
Nina Khanna1, Luigia Elzi1, Nicolas Müller2, Christian Garzoni3, Christoph Fux4, Matthias Cavassini5, Pietro Vernazza6, Enos Bernasconi7, Manuel B
Patients in Mafeteng on Antiretroviral Therapy (PIMA) - a cross-sectional study of patients receiving antiretroviral treatment (ART) in Lesotho
Claudia Kircher1, Piet Mc Pherson2, Mtate Tsasanyana3, Me Rantequa3, Jan Bergmann1, Reinhard Brodt4, Shlomo Staszewski1, Tessa Lennemann1
Todesursachen von HIV-Patienten in der Köln-Bonn Kohorte
Caroline Hertenstein1, Joerg Janne Vehreschild1, Jan-Christian Wasmuth2, Tim Kümmerle1, Jürgen Rockstroh2, Gerd Fätkenheuer1
Ongoing syphilis epidemic among HIV-infected men who have sex with men in Austria
Stefanie Gogl1, Mario Sarcletti2, Margret Jöchl3, Armin Rieger4, Maria Geit5, Bernhard Haas6, Ninon Taylor7, Manfred Kanatschnig8, Robert Zangerle
Trends of transmitted drug resistance in Germany: an update of the German HIV-1 seroconverter cohort
Claudia Kuecherer1, Barbara Bartmeyer2, Kathrin Keeren1, Claudia Houareau2, Christian Kollan2, Sybille Somogyi1, Bernhard Bienek3, Stefan Dupke4, Heiko
Transmission of drug resistant HIV in Austria
Margret Jöchl1, Stefanie Gogl2, Armin Rieger3, Mario Sarcletti4, Maria Geit5, Bernhard Haas6, Ninon Taylor7, Manfred Kanatschnig8, Robert Zangerle
Epidemiology of primary drug resistance in chronically HIV infected patients in Germany
Mark Oette1, Rolf Kaiser2, Thomas Lengauer3, Stefan Reuter4, Nadine Sichtig2, Gerd Fätkenheuer5, Jürgen K Rockstroh6, Heribert Knechten7, Stefa
Hepatitis B- (HBV) and hepatitis C- (HCV) co-infection in patients with a known date of HIV-infection in the German HIV-1-seroconverter-cohort
Nadine Spielmann1, Barbara Bartmeyer1, Claudia Houareau1, Claudia Kücherer1, Christina Lindemann1, Osamah Hamouda1
Minority quasispecies of drug-resistant viruses in acutely HIV-1 infected patients in Hamburg, Germany: prevalence patterns and time-trends
Hans-Jürgen Stellbrink1, Christian Noah2, Karin Metzner3
Concomitant diseases in HIV-positive persons (PLWHA) in Germany - a comparison between sexes on basis of the KompNet cohort
Klaus Jansen1, Norbert H. Brockmeyer1,2, Monika Baudewig3, Ravi Walli3, Burkhard Haastert4, Matthias Freiwald5, Thomas Harrer6, Shlomo Staszewski7, B.
Frauenspezifische Risikofaktoren für „frühe“ und „späte“ HIV-Diagnosen in Österreich
Margret Jöchl1, Stefanie Gogl1
Identification of a novel recombinant form of HIV-1 in Switzerland
Daniel H Paris1,2, Roberto F Speck1, Jürg Böni3
Treatment interruptions (TI) of antiretroviral combination therapy (cART) in the German ClinSurv cohort 2005-2008
Christian Kollan1, Claudia Houareau1, Barbara Bartmeyer1, Andrea Kühne1, Osamah Hamouda1, for the ClinSurv Study Group
Epidemiological situation of STI in the border region Vienna/Austria: results of the BORDERNET sentinel surveillance
Klaus Jansen1, Andreas Gilsdorf1, Elfriede Steffan2, Osamah Hamouda1, Viviane Bremer1
HIV patient care under real life conditions: experiences from the southwestern german cohort
Jens Kittner1, Ana Paula Barreiros1, Bernd Claus2, Martin Däumer3, Kurt Fischer4, Georg Friese5, Jürgen Lohmeyer6, Thomas Rath7, Ansgar Rieke
Recent antiretroviral treatment (ART) practice in Germany - results from the ClinSurv multicenter cohort
Christian Kollan1, Andrea Kühne1, Barbara Bartmeyer1, Osamah Hamouda1, for the ClinSurv Study Group
High influence of migration and sex-work on the epidemiological situation of STI in Vienna/Austria: results of the BORDERNET sentinel-surveillance
Klaus Jansen1, Andreas Gilsdorf1, Elfriede Steffan2, Osamah Hamouda1, Viviane Bremer1
Impact of 44 months cART-dispensing on HIV-care in rural south-central Tanzania
Erik Mossdorf1,2,3, Geofrey Mwaigomole1, Evarist Chiweka1, Patience Kibatala4, Christoph Hatz3, Manuel Battegay5, Marcel Stoeckle3,5
The influence of genotypic resistance testing on antiretroviral first-line treatment decision in the German HIV-1-seroconverter-study-group
Claudia Houareau1, Barbara Bartmeyer1, Claudia Kücherer2, Nadine Spielmann1, Christian Kollan1, Christina Lindemann1, Osamah Hamouda1, German Serokonverter Stu
Factors associated with adverse pregnancy outcome in HIV positive women: evidence from the Swiss Mother and Child HIV cohort study
Karoline Aebi-Popp1, Louise Vilén2, Tracy Glass3, Olav Lapaire1, Irene Hoesli1, Mother and Child HIV Cohort Study
Self-reported history of STI and STI-related utilization of the German health care system by MSM
Axel J. Schmidt1, Ulrich Marcus1
The spectrum of malignancies in the era of HAART
Martin Vogel1, Oliver Friedrich1, Tobias Höller2, Jan-Christian Wasmuth1, Evrim Anadol1, Carolynne Schwarze-Zander1, Bernd Holleczek3, Jürgen Kurt Rockstr
Increasing prevalence of syphilis in MSM with known date of HIV-infection from the German HIV-1 seroconverter study
Ulrich Marcus1, Claudia Kücherer2, Axel J. Schmidt1, Barbara Gunsenheimer-Bartmeyer1, Christina Lindemann1, Nadine Spielmann1, Osamah Hamouda1, German HIV-1 Ser
HBV genotype diversity in HIV/HBV co-infected patients in the Swiss HIV cohort
Florian Bihl1, Gladys Martinetti2, Bruno Ledergeber3, Sandrine Estoppey Younes4, Rainer Weber3, Pietro Vernazza5, Manuel Battegay6, Hans Jakob Furrer7,
Switching to raltegravir in HIV-infected patients with well controlled viral load - efficacy and safety
Stefan Mauss1, Ana Milincovic2, Florian Berger1, Julia Henke1, Guenther Schmutz1, Petra Hegener1, Dieter Kuschak3, Stephan Schauseil3, Jospe Mallolas
HIV integrase inhibition - more complex that simply blocking one key viral enzyme function
Séverine Louvel1, François Hamy2, Thomas KIimkait1
New antiretroviral treatment options with integrase-inhibitors, CCR5-antagonists and second-generation-NNRTI and combination antiretroviral therapy (cART) in the ClinSurv cohort
Barbara Bartmeyer1, Kollan Christian1, Kühne Andrea1, Osamah Hamouda1, Studiengruppe Klinische Surveillance ClinSurv
Final results from the Connect cohort confirm efficacy and safety of enfuvirtide in a "real life setting "
Olaf Degen1, Gerd Faetkenheuer2, J Bogner3, S Dupke4, S Koeppe5, S Gute6, W Becker7, A Tappe8, Egbert Wellmann8, Hans-Juergen Stellbrink
Treatment of HIV-infected patients with a HAART regimen containing Enfuvirtide and a “second generation” protease inhibitor
Thore Lorenzen1, Irene Walther1, Johannes R. Bogner2, Jan van Lunzen3, Christoph Schuler4, Gerd Fätkenheuer5, Peter Gute6, Carl-Knut Schewe7, Siegfr
Opportunities to assessan optimized salvage regimen in HIV infected triple-class experienced patients by the expert advice system RADATA
Thore Lorenzen1, Irene Walther1, Peter Gute2, Johannes R. Bogner3, Stefan Mauss4, Matthias Stoll5, Heribert Knechten6, Jürgen Rockstroh7, Jan van L
Maraviroc in clinical practice - 24 weeks data
Heribert Knechten1, Christian Höhn1, Robert Ehret1, Frank Wiesmann1, Martin Hower2, Stefan Scholten3, Anton Neuwirth4, Wolfgang Köthemann4, Pa
Durable efficacy and safety of etravirine in treatment-experienced, HIV-1-infected patients: pooled Week-96 results from the phase-III DUET-1 and DUET-2 trials
J Vingerhoets1, B Woodfall1
Safety and efficacy of tenofovir DF (TDF) in combination with 3TC and efavirenz (EFV) in antiretroviral-naïve patients through seven years
Isabel Cassetti1, Jose Valdez R. Madruga2, Arnaldo Etzel3, Jamal Muhamad A.H. Suleiman4, Britta Ranneberg5, Lijie Zhong6, Andrew Cheng6, Jeffrey Enejosa6,
The 48-week efficacy and safety of switching to fixed dose efavirenz/emtricitabine/tenofovir DF in HIV-1-infected patients receiving HAART
Edwin De Jesus1, Anton Pozniak2, Markus Bickel3, Joel Gallant4, Jose Arribas5, Yun Zhou6, Andrew Cheng6, Jeffrey Enejosa6
Simplification of therapy (ART) with Efavirenz/Emtricitabine/Tenofovir DF single tablet regimen vs. continued ART in suppressed, HIV-infected patients
B. Young1, E. de Jesus2, J.O. Morales-Ramirez3, Tina Nakonz4, J-F. Maa5, D. Seekins5, A. Farajallah5, R. Ebrahimi6, J. Flaherty6
Safety and tolerability of etravirine (ETR) in hepatitis B and/or C co-infected patients in DUET-1 and 2: 48 week results
Albrecht Stoehr1, Gerd Fätkenheuer2, Klaus Göbels3, Frank-Detlef Goebel4, Hans Jäger5, Arend Moll6, Jürgen Kurt Rockstroh7, Dieter Schuster
Langzeitverträglichkeit und -effizienz von Nevirapin als Bestandteil einer HAART
Ivanka Krznaric1, Stephan Dupke1
Patient reported outcomes after simplification to a single tablet regimen of Efavirenz (EFV)/Emtricitabine (FTC)/Tenofovir DF (TDF)
S. Hodder1, K. Mounzer2, E. de Jesus3, Tina Nakonz4, K. Grimm5, A. Farajallah5, J. Flaherty6
Safety and efficacy of tenofovir in pregnant women
Annette Elisabeth Haberl1, Richard Linde2, Anke Reitter3, Peter Gute4, Gaby Knecht4, Manfred Mösch5, Tessa Lennemann6, Gabriele Nisius6, Christoph
Kivexa versus Truvada: similar virological outcomes in ART-naïve patients starting a lopinavir/ritonavir-based regimen. 48-week-data from the STAR and STELLA cohorts
Eva Wolf1, Axel Baumgarten2, Bernhard Bieniek3, Stefanie Holm4, Martin Hower5, Hans Jaeger6, Thomas Lutz7, Markus Mueller8, Wolfgang Schmidt9
Efficacy and safety of TDF/FTC-containing first line HAART in clinical practice - two year data from the German outpatient cohort
Jan van Lunzen1, Gerd Fätkenheuer2, Thomas Lutz3, Stephan Klauke4, Stefan Mauss5, Carl Knud Schewe6, Heribert Knechten7, Patrick Braun7, Lothar Ga
Gutes Ansprechen einer Kombinationstherapie von Trizivir/Tenofovir bei Vorbehandelten über 96 Wochen. CTP-Score vs.1.2 als prädiktives Tool für den Therapieerfolg
Stephan Dupke1, Bettina Hintsche1, Christoph Mayr1, Frank Schlote1, Arend Moll1, Felise Krauthausen1, Daniel Prziwara1, Dorothea Schleehauf1, Siegfried
48-wk safety and efficacy of darunavir/ritonavir (DRV/r) in treatment-experienced children and adolescents in DELPHI
P Vis1, V Sekar1, B Van Baelen1, S Spinosa-Guzman1
Efficient suppression of minority quasispecies of drug-resistant viruses present at primary HIV-1 infection by boosted protease inhibitor containing ART
Karin J Metzner1, Pia Rauch2, Viktor von Wyl1, Herbert Kuster1, Jürg Böni3, Rainer Weber1, Huldrych F Günthard1
Efficacy and safety of 48 weeks maintenance with once-daily ATV vs ATV/r in suppressed patients after induction with ATV/r
J-F Delfraissy1, S Moreno2, J Sanz-Moreno3, G Carosi4, V Pokrovsky5, A Lazzarin6, G Pialoux7, A Balogh8, E Vandeloise8, I Scheirich9
Low nadir CD4 count predicts failure of LPV/r monotherapy (MOST) due to unexpectedly high failure rate in monotherapy arm
Christine Gutmann1, Milos Opravil2, Christoph Fux3, Hansjakob Furrer3, Laurent-Arthur Decosterd4, Matthias Cavassini4, Sabine Yerly5, Bernard Hirschel5,
Cost effectiveness analysis of atazanavir versus lopinavir in the treatment of naïve HIV patients in Germany
Per-Olof Thuresson1, Iris Scheirich2, Aljoscha S Neubauer2, Bart Heeg1
Vergleich der Kosten-Nutzen-Relation verschiedener Proteaseinhibitoren bei der Erstlinien-Therapie von HIV-Patienten unter Anwendung der vom IQWIG vorgeschlagenen Methode der Effizienzgrenze
Verena Donatz1, Erik Smets2, Andrew Hill3, Matthias Stoll4
Efficacy and safety by baseline HIV-RNA and CD4-count in treatment-naive patients treated with Atazanavir/r and Lopinavir/r in the CASTLE study
J Uy1, R Yang1, A Thiry1, J Absalon1, A Farajallah1, J Maa1, E Grützner2, I Scheirich2, D McGrath1
Susceptibility of diverse HIV-1 patient isolates to the maturation inhibitor, bevirimat, is setermined by clade-specific polymorphisms in Gag CA-SP1
Thomas Klimkait1, Karl Salzwedel2, Severine Louvel1, M Sakalian2, M Reddick2, C Finnegan2, D Martin2, S Mc Callister2, Francois Hamy1, G Al
Once-daily draunavir used in routine clinical care produces trough Darunavir-drug-concentrations in excess of 30x the protein-corrected (PC)EC50 for wild-type HIV
Claire Robertson1, A. N. Jayasuriya1, C. Smith2, N. Dufty1, A. Berry1, C. Stradling1, Steve Taylor1
Lopinavir/ritonavir plus atazanavir in comparison to lopinavir/ritonavir plus nucleoside analogues (zidovudin plus lamivudin) - the LORAN-trial, A Phase III-study
Kai Ulbricht1, Matthias Stoll1, Georg M. Behrens1, Bernd Salzberger2, Heiko Jessen3, Arne Jessen3, Birger Kuhlmann4, Hans Heiken4, Andreas Trein5
Long term outcome of 8 infants, which started treatment with 2 NRTI + Nelfinavir in the first year of life
Bernd Buchholz1, Steffen Hien1, Matthias Beichert1, Matthias Dürken1, Horst Schroten1
Health-related quality of life (HRQoL) improvement in antiretroviral-naive HIV-infected patients on atazanavir/r or lopinavir/r regimens: week 24 results from AI424138
J Su1, J Absalon1, M Mancini1, U Iloeje1, N Strobl2, I Scheirich2, D McGrath1
Gender differences in ART-naive patients initiating a lopinavir/ritonavir-based regimen. 48 week data from the German STAR and STELLA cohorts
Christine Koegl1, Axel Baumgarten2, Bernhard Bieniek3, Stefanie Holm4, Martin Hower5, Hans Jaeger6, Thomas Lutz7, Markus Mueller8, Wolfgang Schmidt
Starting a Lopinavir/r-based regimen in ART-naive patients improves quality of life. 48-week data from the German STAR and STELLA cohorts
Christine Koegl1, Axel Baumgarten2, Bernhard Bieniek3, Stefanie Holm4, Martin Hower5, Hans Jaeger6, Thomas Lutz7, Markus Mueller8, Wolfgang Schmidt
Safety analysis of darunavir/r (DRV/r): combined data from randomised Phase II and Phase III studies
Gerd Fätkenheuer1, Keikawus Arasteh2, Johannes Bogner3, Frank-Detlef Goebel4, Thomas Harrer5, Hans Jäger6, Jörg-Andres Rump7, Dieter Schuster8<
German cost-efficacy analysis to achieve full virological suppression for treatment experienced HIV infected patients in the DUET trials
Matthias Stoll1, Verena Donatz2, Silas Martin3, Andrew M Hill4
HIV RNA levels six months after antiretroviral therapy initiation predict subsequent survival and retention of HIV-1-infected individuals in Sub-Saharan Africa
Maria Cristina Marazzi1, Leonardo Palombi2, Ersilia Buonomo2, Paola Scarcella2, Giovanna Paturzo3, Anna Maria Doro Altan2, Susanna Ceffa3, Dieter Wanderlein4,
Retrospektive Datenerhebung über den Zeitpunkt des Therapiebeginns bei HIV positiven Frauen in zwei Zentren Deutschlands von 1995-2008
Ivanka Krznaric1, Alexander Zoufaly2, Sandra Hertling3
Antiretrovirale Therapie bei einem extremen Frühgeborenen
David Endress1, Richard Linde2, Doris Fischer3, Elisabeth Förster-Waldl4, Wolfhart Kreuz2, Andreas Lischka1, Christoph Königs2
Atazanavir plasma concentrations substantially decreased in HIV-1 infected adults taking concomitantly methadone oral solution in a daily observed therapy
Annette Haberl1, Christoph Stephan1, Manfred Mösch2, Gabi Nisius1, Tessa Lennemann1, Pavel Khaykin1, Michael Kurowski3, Schlomo Staszewski1, Reinhard Bro
Pharmacokinetics and dose selection of etravirine (ETR) in HIV-infected children between 6 and 17 years, inclusive
Christoph Königs1, Cornelia Feiterna-Sperling2, Susanna Esposito3, Carlo Giaquinto4, Thomas Kakuda5, Rekha Sinha6, Rebecca Mack5, Katrie Janssen6,
Prevalence of virologic failure in HIV-1-infected patients treated with antiretroviral therapy (ART) - results from a German multicenter cohort-study (VIREMIA)
Axel Baumgarten1, Stephan Klauke2, Knud Schwere3, Christoph Mayr4, Hans Jäger5, Pavel Khaykin6, Cam-Tuan Tran7, Markus Bickel6
Veränderungen des HIV-1-Mutationsprofils vor Therapiebeginn in Abhängigkeit von der Zeit
Stefan Reuter1, Rolf Kaiser2, Mark Oette3, Melanie Balduin2, Björn Jensen1, Dieter Häussinger1, Nadine Sichtig2
Use of tenofovir disoproxil fumarate (TDF) during pregnancy: an analysis from the Antiretroviral Pregnancy Registry (APR)
Bruce Olmscheid1, Sandra Hertling2, Sherry Zhang1
Efficacy of a computerised physician reminder system to control CHD risk factors in HIV-patients receiving cART (Swiss HIV Cohort Study)
Heiner C. Bucher1, Martin Rickenbach2, James Young1, Tracy Glass1, Yannick Valley2, Enos Bernasconi3, Matthias Cavassini4, Christoph Fux5, Véronique
Prevalence of minority HIV-1 NNRTI drug resistance mutation K103N in antiretroviral treatment-naïve patients
Patrick Braun1, Robert Ehret1, Christian Höhn1, Frank Wiesmann1, Heribert Knechten1
Tenofovir- and protease inhibitor-use are associated with an Increased prevalence of proximal renal tubular dysfunction in the SHCS
Christoph Andreas Fux1, Milos Opravil2, Matthias Cavassini3, Alexandra Calmy4, Ben Spycher5, Barbara Hasse2, Patrick Schmid6, Marcel Stöckle7, Vanin
12 h pharmacokinetics in HIV mono- and HIV/HCV co-infected patients
Martin Vogel1, Norbert Bertram2, Jan-Christian Wasmuth1, Christoph Wyen3, Esther Voigt1, Carolynne Schwarze-Zander1, Thomas Sudhop4, Gerd Fätkenheuer3
Impact of resistant HIV on first line treatment response in therapy naive patients of the German HIV-1-seroconverter cohort
Barbara Bartmeyer1, Claudia Houareau1, Claudia Kücherer2, Christian Kollan1, Johanna Werning1, Osamah Hamouda1, Deutsche HIV-1 Seroconverter Studiengruppe
Quantitative and qualitative mtDNA-lesions with mitochondrial dysfunction in multiple organs after HAART-associated fatal lactacidosis
Jan Thoden1, Dirk Lebrecht1, Nils Venhoff1, Jens H Neumann2, Klaus Müller3, Ulrich A Walker1
Coronary heart disease and risk factors in HIV-1-infected patients in correlation to abacavir treatment
Thomas Harrer1, Almut Taubald1, Ellen G. Harrer1, Christina Schaub-Koch1, Anja Reisch1, Sandra M. Müller1, Bernd Spriewald2, Mohamed Marvan3, Frank
Detection of abacavir hypersensitivity by ELISpot method
Stefan Esser1, Robert Jablonka1, Falko M. Heinemann2, Monika Lindemann2
A German cohort of 54 HIV and LPV/r exposed pregnancies - pharmacokinetics, placental transfer and pregnancy outcome
Milena Sovric1, Andrea Gingelmaier1, Ralph Kaestner1, Tobias Weissenbacher1, Ionnis Mylonas1, Klaus Friese1
Frequent pyridoxal phosphate (PLP) inadequacy associated with the use of RTV-boosted protease inhibitors
Hans-Jürgen Stellbrink1,2, Andreas Lämmel2, Christian Noah2
Transmission of a highly RT-and protease-inhibitor resistant virus demonstrates the importance of resistance analysis prior to initiation of HAART
Thomas Harrer1, Klaus Korn2, Hauke Walter2, Sandra M. Müller1, Werner Matek3, Ellen G. Harrer1, German Competence Network for HIV/AIDS
Frequency of lipodystrophy in a large observational cohort using either LPV/r or EFV
Jan van Lunzen1, Ramona Volkert-Pauli2, Stefan Hansen3, Martin Hower4, Clemens Scheidegger5, Antonius Mutz6, Andreas Trein7
The definition "acute" does not influence SVR in HIV-positive individuals treated with pegylated interferon +/- interferon after acute HCV infection
Martin Vogel1, Axel Baumgarten2, Kevin Ummard3, Michael Rausch4, Knud Schewe5, Christoph Mayr6, Dietmar Schranz7, Albert Theisen8, Heiko Jessen9
Leberparenchymschaden bei HIV-1-Monoinfizierten unter antiretroviraler Therapie (ART) und chronischer Transaminasenerhöhung
Patrick Ingiliz1, Marc-Antoine Valantin2, Claudine Duvivier3, Fadia Medja4, Stephanie Dominguez3, Frédéric Charlotte5, Roland Tubiana3, Thierry Poynard
Methicillin resistant Staphylococcus aureus and ESBL-producing Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca isolated from HIV infected inpatients
Hartmut Stocker1, Bettina Eberspaecher2, Hubert Schulbin1, Christian Traeder1, Sonja Swidsinski3, Keikawus Arasteh1
Vergleich von TST, QuantiFERON-Gold In-Tube und T-Spot.TB bei HIV-Patienten
Christoph Stephan1, Timo Wolf1, Udo Götsch2, Oswald Bellinger2, Gabriele Nisius1, Gerhard Oremek3, René Gottschalk2, Sonja Stark2, Hans-Reinha
Anales Dysplasiescreening bei HIV-infizierten Frauen
Andrea Gingelmaier1, Tobias Weissenbacher1, Kästner Ralph1, Bernd Kost1, Thomas Grubert2, Sovric Milena1, Florian Bergauer1
Streptococcal proctitis resembling gonorrhoea in HIV infected men who have sex with men
Anja Potthoff1, Alexander Kreuter1, Norbert H. Brockmeyer1, Competence Network for HIV/AIDS
Anorectal Chlamydia trachomatis infections in Swiss HIV-infected homosexual men
Thanh Dang1, Katia Jaton2, Markus Flepp3, Helen Kovari4, Jonh-Marc Evison5, Jan Fehr6, Patrick Schmid7, Emmanuelle Boffi El Amari8, Massimo Odorico
Incidence of bacterial, fungal or viral co-infection in HIV-positive individuals with PCP: a retrospective analysis of the AVK cohort
Christian Traeder1, Susann Kowoll1, Hartmut Stocker1, Keikawus Arastéh1
Wirksamkeit einer anti-retroviralen Therapie (HAART) bei Patienten mit HBV-HIV Koinfektion
Kosi Lana1, Thomas Reiberger1, Katharina Pfistershammer2, A. Rieger2, Markus Peck-Radosavljevic1
Hepatitis C coinfection in HIV-infected patients - evidence for considerable undertreatment
Axel Baumgarten1, Christian Hoffmann2, Lutwin Weitner2, Arend Moll3, Christiane Cordes4, Frank Schlote5, Heinz-August Horst6, Siegfried Köppe7, Bet
Antivirale Effektivität von Interferon bei immunkomprimierten HCV Patienten nach Lebertransplantation oder mit HIV Koinfektion
Thomas Reiberger1, Susanne Rasoul-Rockenschaub2, Peter Ferenci1, Armin Rieger3, Markus Peck-Radosavljevic1
Ribavirin-Plasmakonzentrationen in der antiviralen Therapie der chronischen Hepatitis C
Hartwig Klinker1, Werner Heinz1, Isabell Trebesch1, Christine Guhl1, Andreas Trein2, Gudrun Tossing3, Peter Langmann4
Simultane Radiochemotherapie des Analkarzinoms bei HIV-positiven Patienten unter HAART
Ingeborg Fraunholz1, Anette Haberl2, Claus Rödel1
Beschleunigte Fibroseprogression und portale Hypertension bei HIV-HCV koinfizierten Patienten mit niedrigem CD4+ Nadir
Thomas Reiberger1, Arnulf Ferlitsch1, Wolfgang Sieghart1, Florian Breitenecker2, Armin Rieger2, Brigitte Schmied3, Markus Peck-Radosavljevic1
The relevance of CMV viremia, in the HAART era
Emmanuelle Boffi El Amari1, Christophe Combescure1, Sabine Yerly1, Alexandra Calmy1, Laurent Kaiser1, Bernard Hirschel1, Swiss HIV Cohort Study
High risk of mamma carcinoma in HIV infected men
Anja Potthoff1, Klaus Jansen2, Martin Doerler1, Claudia Michalik3, Norbert H. Brockmeyer1, Competence Network for HIV/AIDS
HBV-markers in HIV-treatment naive patients from the RESINA-cohort
Frank Wilhelm1, Nadine Sichtig1, Eugen Schülter1, Jens Verheyen1, Herbert Pfister1, Mark Oette2, Rolf Kaiser1, Gerd Fätkenheuer3, Thomas Lengauer
High dose chemotherapy followed by autologous stem cell transplantation in HIV-related lymphoma or germ cell tumor: the Munich experience
Marcus Hentrich1, Tim Röhnisch2, Arthur Gerl3, Clemens Scheidegger4, Eva Jägel-Guedes5, Christoph von Schilling6, Thomas Sternfeld7, Xaver Schiel8
Rupia syphilitica bei HIV-positiver Patientin
Ahmad Jalili1, Martin Mosleh1, Katharina Pfistershammer1, Armin Rieger1
Untersuchung zur Bedeutung der Syphilis bei MSM mit HIV Ko-Infektion
Alexander Bubnov1, Janine Zweigner2, Carmen Zedlack1, Heiko Jessen1
Conservative antibiotic management of infected totally implantable venous access devices (TIVAD). A retrospective analysis of the AVK cohort
Marlen Wieczorek1, Christian Traeder1, Dirk Hampf1, Keikawus Arastéh1
Meningomyelitis complicating primary HIV infection
Hubert Schulbin1, Hartmut Stocker1, Siegfried Köppe2, Peter Kreckel2, Keikawus Arasteh1
Identical liver fibrosis in a cohort of HIV/HCV-coinfected patients on HAART as compared to HIV-negative HCV-patients assessed by transient elastography
Frank Grünhage1, Jan-Christian Wasmuth2, Simon Herkenrath2, Natascha Vidovic3, Georg Goldmann3, Jürgen Rockstroh2, Frank Lammert1, Johannes Oldenburg
Severe Leucencephalopathy as aseptic form of immune reconstitution inflammatory syndrome in the brain in Caucasian and African patients
Adrian Ringelstein1, Christian Oelschlaeger2, Ingo W Husstedt2, Christian Mathys1, Andreas Saleh1, Gabriele Arendt3
Autonomous nervous system activity and glucose metabolism in HIV-patients receiving antiretroviral therapy
Maximiliane Wiese1, Michael Kaspari1, Ulrike Möbius1, Reinhold E Schmidt1, Georg M Behrens1
Do changes of fractional anisotropy predict loss of cognitive functions in HIV patients?
Bianca Stubbe-Dräger1, Michael Deppe1, Siawoosh Mohammadi1, Harald Kugel2, Nora Gregor1, Stefan Evers1, Erich-B. Ringelstein1, Gabriele Arendt3, St
Characterization of revertant HIV from patients in the German seroconverterstudy: viral fitness and in vitro selection of AZT resistance
Kathrin Keeren1, Livia Schünadel1, Eva Brandt1, Sybille Somogyi1, Klaus Fischer2, Bettina Hintsche3, Gerd Klausen3, Heiko Jessen4, Barbara Bartmey
Delayed detection of HIV seroconversion using a 4th generation HIV rapid test
Gerrit Mohrmann1, Hans-Jürgen Stellbrink2, Christian Noah1
Predictors for CXCR4-tropism: CD4-nadir and the use of the enhanced sensitivity (ES) trofile assay
Eva Wolf1, Patrick Braun2, Lothar Schneider3, Anna Balogh1, Heribert Knechten2, Martin Karwat4, Franz Mosthaf5, Albrecht Ulmer6, Robert Ehret2
HIV coreceptor tropism in treatment-naive patients newly diagnosed at a late stage of HIV-infection
Benedikt Simon1, Armin Rieger2, Mario Sarcletti3, Brigitte Schmied4, Elisabeth Puchhammer-Stöckl1
Selection of peptide ligands for CXCR4-using HIV-1 by the phage display technology
Ralf Duerr1, Kalle Möbius2, Oliver Sander3, Jutta Eichler2, Ursula Dietrich1
Performance of genotypic coreceptor measurement using geno2pheno[coreceptor] in B- and non-B HIV subtypes in a large cohort of therapy-experienced patients
Hauke Walter1, Eva Wolf2, Patrick Braun3, Martin Däumer4, Alexander Thielen5, Christian Noah6, Nadine Sichtig7, Harm Müller8, Martin Stü
Development of antigen-based capture ELISA for serodiagnosis of GB Virus C infection in HIV patients
Mandy Richter1, Susan Jung1, Bernhard Fleckenstein1, Heide Reil1
Underestimation of HIV-1 RNA levels in a commercial real-time PCR assay: reasons and consequences
Klaus Korn1, Benedikt Weißbrich2, Cornelia Henke-Gendo3, Albert Heim3, Ninon Taylor4, Ramona Pauli-Volkert5, Josef Eberle6
Fallbericht: Anhaltend grenzwertiger Westernblot trotz gesicherter HIV-Infektion mit übertragener Multiresistenz
Jens Martin Kittner1, Martin Däumer2, Bernhard Thiele2, Thomas Mertes3, Ana-Paula Barreiros1, Marcus Schuchmann1, Ansgar Rieke4
Longitudinal modeling of the influence of genetic variants identified through genome-wide analyses and antiretroviral therapy to dyslipidemia in HIV-infected patients
Margalida Rotger1, Patrick Taffé2, Amalio Telenti1, Philip Tarr3, Swiss HIV Cohort Study
Integration of structured counseling for smoking cessation in HIV outpatient care
Milo Huber1, Rainer Weber1, Bruno Ledergerber1, and the SHCS
Reprogramming of CD8+ T cells with an HIV-1-specificity by TCR-RNA electroporation
Christian Hofmann1,2, Thomas Harrer1, Kathrin Eismann1, Silke Bergmann1, Verena Kubesch2, Ellen Harrer1, Gerold Schuler2, Jan Dörrie2, Niels Schaf
Kinderwunschberatung bei HIV-infizierten Frauen
Andrea Gingelmaier1, Katja Wiedenmann1, Ralph Kästner1, Milena Sovric1, Marianne Müller1, Ulrike Sonnenberg-Schwan2, Katharina Weizsäcker3
Erste HIV-1/2 Doppelinfektion in Österreich - ein Fallbericht
Wolfgang Prammer1, Josef Eberle2, Walter Aichinger1
What do HIV-infected patients die of today?
Silja Bühler1, Julia Söllner1, Ulrich Seybold1, Johannes R Bogner1
Der Beginn der Transmissionsprophylaxe in der 32. Schwangerschaftswoche scheint zu spät zu sein - Daten aus Hamburg
Sandra Hertling1, Karen Olah2, Irene Walther2, Rainer Laux3, Rainer Ganschow4, Mareike Sornsakrin4, Stefan Hansen5, Kristin Lauterbach6, Sonja Gudowius
Virological medical quality management - 9 years follow-up
Patrick Braun1, Christian Höhn1, Frank Wiesmann1, Robert Ehret1, Heribert Knechten1
Successful HIV1-Post-Expositionprophylaxis in 7 extremely premature newborns (birth weight < 1500g) with several risks of HIV1-transmission
Steffen Hien1, Bernd Buchholz1, Matthias Beichert2, Thomas Schaible1, Horst Schroten1
Single balloon enteroscopy (SBE): findings in the small intestine in HIV infected individuals: a prospective study of the AVK cohort
Julia Brümmer1, Christian Träder1, Keikawus Arastéh1
10 Jahres-Jubiläum von HIVmobil: Verein für HIV-spezifische medizinische Hauskrankenpflege und Langzeitpflege sowie Sozialbegleitung für Menschen mit HIV-AIDS in Wien
Wolfgang Steflitsch1, Elisabeth Maurer2, Eva Stifter2, Beate Dannoritzer2, HIVmobil
Late HIV presentation at the Chronic Diseases Clinic (CDCI) of the rural St. Francis Designated District Hospital, Ifakara Tanzania
Nadja Heuer1,2,3, Marcel Stoeckle2,4, Boniphace Jullu5, Rehema Mchomvu1, Penelope Vounatsou2, Patience Kibatala6, Hansjakob Furrer7, Manuel Battegay4, C
Entwicklung einer Hochqualitätsversorgung in der ambulanten Betreuung von HIV infizierten Patienten in Kamerun
Stefan Schmiedel1, Torsten Feldt2,3,4,5, Nchang Taka6, Jonah Wefuan6, Gerd Dieter Burchard1,2, Jan van Lunzen1
3OD - once daily (OD) TDF-containing HAART in HIV-1-infected former IVDU patients receiving opiate substitution: efficacy, tolerability and adherence
Stefan Esser1, Schlomo Staszewski2, Annette Haberl2, Fiona Mulcahy3, Jörg Gölz4, Andreas Körber1, Britta Ranneberg5, Lothar Gallo5, Thoma
Experience patients treated by outpatient clinics or by private practitioners differing treatment characteristics and clinical outcomes in Germany?
Klaus Jansen1, Norbert H. Brockmeyer1, Burkhard Haastert2, Axel Baumgarten3, A. Stoehr4, Georg Behrens5, Hans Jaeger6, Helmut Hartl7, A. Mutz8
HIV- positive Frauen können auch in Deutschland vaginal gebären - Erfahrungen mit 50 vaginal intendierten Geburten 2001 bis 2008
Ralph Kästner1, Andrea Gingelmaier2, Milena Sovric2, Marianne Müller2, Ulrike Sonnenberg-Schwan3, Weizsäcker Katharina4
Training and education programme in the European AIDS Treatment Network NEAT
David Hans-U. Haerry1, Manuel Battegay1, Stefano Vella2
Ein Praxisprogramm zur Unterstützung der Therapiebereitschaft und Adherence bei Menschen mit HIV
Susanne Stoelzl1, Dunja Nicca1, Helene Weyermann1, Patrick Schmid1, Pietro Vernazza1
Distinct viral interference mechanisms by different GBV-C proteins on HIV replication
Kristin Hänel1, Susan Jung1, Holger Wend1, Bernhard Fleckenstein1, Heide Reil1
Uncoupling gag and pol reading frames reveals p6*´s role as spacer protein in HIV
Andreas Leiherer1, Christine Ludwig1, Ralf Wagner1
Einfluss des CTLA4+49A>G Polymorphismus auf das Ansprechen auf eine HCV spezifische Therapie bei HIV-positiven Patienten mit einer akuten Hepatitis C
Benjamin Krämer1, Martin Vogel1, Hans Dieter Nischalke1, Monika Michalk1, Tilman Sauerbruch1, Ulrich Spengler1, Jürgen Rockstroh1, Jacob Nattermann1
Is the cellular RNA helicase DDX3 a new potential antiviral target for HIV-1?
Sandra Beermann1, Giovanni Maga2, Ursula Dietrich1
Mitogenic and adjuvant properties of a multimeric CD40 ligand variant on the surface of HIV-1 C-Clade Pr55gag VLP
Simon Bredl1, Josef Köstler1, Jens Wild1, Ralf Wagner1
Sequence and structure information from V3 as basis for a sensitive genosorting method to determine HIV coreceptor use
Heinz Stucki1, Sarah Wagner1, Vincent Vidal2, François Hamy2, Thomas Klimkait1
Influence of major protease inhibitor resistance mutations on CTL recognition
Sandra Michaela Müller1, Silke Bergmann1, Pia Rauch1, Kathrin Eismann1, Angela Hückelhoven1, Jennifer Etschel1, Bernd Spriewald2, Ellen Harrer1
Relocation and higher apoptosis of plasmacytoid dendritic cells in lymphoid tissues of HIV-1 infected patients
Clara Lehmann1, Norma Jung1, Jan van Lunzen2, Gerd Fätkenheuer1, Fabio Romerio3, Pia Hartmann1
Interference with the genome of HIV as therapeutic means to block infection
Verena Oberhauser1, Wilfried Posch1, Doris Wilflingseder1, Brigitte Müllauer1, Stefan Piper2, Birgit Werner2, Thomas Lindhorst2, Holger Bock2, Heri
Expansion of CD56-CD16+ NK cells in HIV infection correlates with differential expression patterns of CCR7 and CD57
Henoch Hong1, Johanna Eberhard1, Phillip Keudel1, Nupur Bhatnagar1, Reinhold E. Schmidt1, Dirk Meyer-Olson1
Inhibition of HIV-1 replication by interference with the ESCRT-I subunit Tsg101
Ilona Hauber1, Jan Chemnitz1, Birgit Schäfer1, Joachim Hauber1
GB Virus C die biologische Alternative zu Maraviroc, T20 & Co
Susan Jung1, Heide Reil1
Reduction of HIV infectivity by GB Virus C anti-E2 antibodies
Susan Jung1, Norbert Donhauser1, Bernhard Fleckenstein1, Heide Reil1
Identification of PD-1 as a unique marker for discordant immune response in HIV infected patients
Katharina Pfistershammer1, Armin Rieger1, Peter Steinberger2, Norbert Kohrgruber1,3
Mitochondrial DNA depletion, mitochondrial dysfunction and peripheral lipoatrophy
Metodi V Stankov1, Reinhold E Schmidt1, Georg M Behrens1
HIV-1 Vpr inhibits type I interferon production by plasmacytoid dendritic cells (pDCs) and impairs pDC-NK cell crosstalk in vitro
Henoch Hong1, Nupur Bhatnagar1, Ulrich Schubert2, Matthias Ballmaier3, Thorsten Volgmann4, Reinhold E. Schmidt1, Hans Heiken1, Dirk Meyer-Olson1
Design of highly efficient fluorescent hydrolysis probes for real-time PCR of HIV-1 nucleic acids with broad cross-clade coverage
Claudia Althaus1, Sara Gianella1, Philip Rieder1, Viktor Von Wyl1, Barbara Niederöst1, Beda Joos1, Huldrych F. Günthard1, Marek Fischer1
Combating drug resistance - antiretroviral activity and immune function in presence of hypusination inhibitors
Philip Hartjen1, Marcel Krepstakies2, Silke Kummer1, Ilona Hauber2, Joachim Hauber2, Jan van Lunzen1
Accumulation of terminally differentiated cells in the CD4+ T-cell population of immunological non-responders
Eva Katharina Meuer1, Sandra Winter1, Norma Jung1, Jan Rybniker1, Gerd Fätkenheuer1, Pia Hartmann1
Parameters of soluble immune activation in vivo correlate negatively with the proliferative capacity of PBMC in vitro in HIV-infected patients
Katharina Kurz1, Christine Winkler2, Mario Sarcletti3, Nikolaus Romani3, Zoltan Banki4, Susanne Ebner3, Dietmar Fuchs2, Robert Zangerle3
Mucosal barrier defect and infiltration with CD4+, CD8+, and perforin+ cytotoxic T cells in early acute HIV infection
Hans-Jörg Epple1, Christoph Loddenkemper2, Kristina Allers1, Michael Fromm3, Jörg-Dieter Schulzke1,4, Martin Zeitz1, Thomas Schneider1
The potential of the Equine Herpes Virus - 1 (EHV-1) vector system as HIV-1 vaccine under safety aspects
Nicole Fiedler1, Helga Hofman-Sieber2, Jens Wild1, Josef Köstler1, Karsten Tischer3, Jens von Einem4, Nikolaus Osterrieder3, Ralf Wagner1
Der Zunahme der Ko-Expression von CD38 und PD-1 auf HIV-spezifischen CD8-T-Zellen folgt ein Anstieg der Viruslast
Thomas Vollbrecht1, Heike Brackmann1, Nadja Henrich1, Jörg Roling1, Ulrich Seybold1, Frank D Goebel1, Johannes R Bogner1, Rika Draenert1
Frequency and impact of drug resistance mutations in previously naïve patients infected with B and non-B HIV-1
Markus Bickel1, Gundolf Schuettfont1, Christoph Stephan1, Stephan Klauke2, Thomas Lutz2, Annette Haberl1, Reinhard Brodt1, Schlomo Staszewski1, Pavel K
Display of HIV-1 envelope epitopes using the mucosal adjuvant Cholera toxin B as a carrier on virus like particles
Ruth Kapzan1, Alexander Kliche1, Ralf Wagner1
Role of organic cation transporters in pathogenesis and therapy of HIV-infection
Norma Jung1, Clara Lehmann1, Andrea Rubbert1, Gerd Fätkenheuer1, Pia Hartmann1, Dirk Taubert2
Uridine supplementation with Mitocnol attenuates mitochondrial cardiomyopathy induced by zidovudine and zalcitabine
Kerstin Balcarek1, Dirk Lebrecht1, Ana C Venhoff1, Catherine Deveaud2, Bertrand Beauvoit2, Jacques Bonnet2, Jan-Bernd Kirschner3, Klaus Müller4, Nil
Impact of zidovudine on adipogenesis
Metodi Stankov1, Reinhold E Schmidt1, Georg MN Behrens1
Soluble CD40 ligand (sCD40L) reduces type I interferon production in HIV-infected subjects after stimulation with CpG oligodeoxynucleotides
Norbert Donhauser1, Martin Helm2, Kathrin Pritschet1, Philipp Schuster1, Moritz Ries1, Klaus Korn1, Sigrun Smola-Hess3, Jörg Vollmer4, Barbara Sch
Instability of HIV-1 antibodies in filter-dried plasma samples stored at room temperature: consequences for its use in incidence tests
Stephan Loschen1, Kristin Strohschein1, Christopher Drewell1, Jörg Bätzing-Feigenbaum2, Ruth Zimmermann2, Osamah Hamouda2, Claudia Kücherer1
Selective expansion of CD56(-)/CD16(+) NK cells in HIV/HCV-coinfection is associated with increased expression of HLA-DR and CD38
Phillip Keudel1, Henoch Hong1, Johanna Eberhard1, Nupur Bhatnagar1, Margot Zielinska-Skowronek1, Julian Schulze zur Wiesch2, Jan van Lunzen2, Reinhold E. Schmidt1
CD4 receptor density on CD4+ T cells is decreased in HIV+ patients with faster disease progression
Annette Audigé1, Patrick Taffé2, Martin Rickenbach2, Pietro Vernazza3, Manuel Battegay4, David Nadal5, Roberto F. Speck1, Swiss HIV Cohort Study
Identification of subdominant CD8+ responses selecting CTL escape mutations in Gag that Impair HIV replication
Arne Schneidewind1,2, Christian Boutwell1, Zabrina Brumme1, Mark Brockman1, Hendrik Streeck1, Chanson Brumme1, Katherine Kane1, Bruce D Walker1, Marcus
T-regulatory cells and T-cell activation in chronic HIV infection
Christian Raphael Kahlert1, Reinhard Maier2, Burkhard Ludewig2, Pietro Vernazza1
Event-related potentials and cerebrospinal fluid markers during HIV-associated neurocognitive disorder
Katrin Biehl1, Thorsten Nolting2, Eleni Koutsilieri3, Peter Young1, Doris Reichelt4, Gabriele Arendt2, Stefan Evers1, Ingo W. Husstedt1, German Competen
Glycosylation and processing of inhibitory C-peptides within the secretory pathway
Andreas Volk1, Joerg Kahle1, Mina Petkova1, Lisa Egerer1, Dorothee von Laer1
Novel concepts for HIV-1 therapy: targeting the interaction of the HIV-1 export factor Rev and its cellular cofactor Sam68
Patricia Skoczylas1, Benedikt Asbach1, Ralf Wagner1
Characterization of a chemokine receptor CCR5-negative T cell line to determine the human immunodeficiency virus type 1 phenotype
Dorothea Binninger-Schinzel1, Benjamin Kraus2, Daniela Müller1, Birgit Krause2, Britta Neumann2, Gudrun Winskowsky2, Timo Wolf3, Reinhard Brodt3, Albrecht
Einfluss der HCV-Koinfektion auf die Expression von sog. “Todes-Rezeptoren“ und deren korrespondierenden Liganden auf CD4+ T-Zellen bei HIV-positiven Patienten
Christian Körner1, Felix Tolksdorf1, Benjamin Krämer1, Daniela Schulte1, Martin Coenen1, Hans-Dieter Nischalke1, Jacob Nattermann1, Jürgen K. Rockstr
GBV-C coinfection in the Bonn HIV cohort: impact on cytokine profile
Carolynne Schwarze-Zander1, Markus Neibecker1, Evrim Anadol1, Jan-Christian Wasmuth1, Martin Vogel1, Ulrich Spengler1, Juergen Kurt Rockstroh1
Uridine supplementation with Mitocnol antagonizes antiretroviral nucleoside analogue-induced mitochondrial peripheral and cerebral neuropathy in vivo
Dirk Lebrecht1, Catherine Deveaud2, Jacques Bonnet2, Jan-Bernd Kirschner3, Klaus Müller4, Nils Venhoff1, Ulrich A Walker5
Isolation and characterization of scFv's from HIV non-progressors (LTNP/EC)
Maria Hertje1, Zhou Mingkui1, Sascha Antoni2, Michael Hust3, Stefan Dübel3, Berta Rodes4, Vincent Soriano4, Markus Bickel5, Ursula Dietrich1<
Interferon-g-mediated pathways and proliferation of HIV-infected peripheral blood mononuclear cells
Katharina Kurz-Schroecksnadel1, Christiana Winkler2, Ernst R. Werner2, Mario Sarcletti3, Nikolaus Romani3, Susanne Ebner3, Dietmar Fuchs2, Robert Zangerle4
Fungal toxins stimulate HIV infection and replication
Cornelia Speth1, Magdalena Hagleitner1, Günter Rambach1, Iradj Mohsenipour2
Pharmacogenetics and personalized care in HIV disease
Amalio Telenti1
Use of resistance data to select treatment regimen: Guidelines and reality
Huldrych Günthard1
Individualized Therapy - Therapy for Individual
Jürgen Rockstroh1
HIV-therapy tomorrow; HIV-therapie morgen
Hansjakob Furrer1
Activation of myeloid cells, triggered by viral replication but not microbial translocation, correlates with disease progression in SIV-infected macaques
Christoph Leinert1, Ulrike Sauermann1, Dietmar Fuchs2, Thomas Schneider3, Christiane Stahl-Hennig1, Sieghart Sopper1
Immunaktivierung und Alterungsprozesse bei HIV
Georg Behrens1
Immunologische Ziele der Therapie und neue Therapieformen
Jan van Lunzen1,2
Global drug policy, the HIV/IDU epidemic in Aastern Europe and Central Asia, and the critical need to scale up opioid substitution therapy
Craig McClure1
Lessons from partnerships Switzerland - Central Asia
Jakob Huber1
PrEP and Microbicides - new approaches to HIV-prevention
Thomas Mertenskoetter1
Progress in AIDS Vaccine Development
Frans van den Boom1
Invasive Fungal Infetions in the Immuno-deficient Patient
Thomas Grünewald
Changing Epidemiology and Consequences for Prevention
Ulrich Marcus